AVXL (Anavex Life Sciences) EPS (Basic): $-0.46 (TTM As of Dec. 2025)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.56
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences EPS (Basic)?

Anavex Life Sciences AVXL -0.97% 30 EPS (Basic) is $-0.46 as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Anavex Life Sciences's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was $-0.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.46.

Anavex Life Sciences's EPS (Diluted) for the three months ended in Dec. 2025 was $-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.46.

Anavex Life Sciences's EPS without NRI for the three months ended in Dec. 2025 was $-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.46.

During the past 3 years, the average EPS without NRI Growth Rate was 4.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Anavex Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 35.30% per year. The lowest was -257.60% per year. And the median was -2.75% per year.

Anavex Life Sciences  (NAS:AVXL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Anavex Life Sciences EPS (Basic) Related Terms

Anavex Life Sciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences EPS (Basic) Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.54 -0.62 -0.60 -0.52 -0.54

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.13 -0.16 -0.11 -0.06
AVXL
30GF Score
Anavex Life Sciences Corp AVXL
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Anavex Life Sciences's Basic EPS for the fiscal year that ended in Sep. 2025 is calculated as

Basic EPS (A: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-46.377-0)/85.289
=-0.54

Anavex Life Sciences's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-5.681-0)/89.029
=-0.06

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.46 mean?
Anavex Life Sciences (AVXL) has a EPS (Basic) of $-0.46 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' EPS (Basic) too high?
Anavex Life Sciences' current EPS (Basic) is $-0.46. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' EPS (Basic) compare to ZNTL and HUMA?
Anavex Life Sciences' EPS (Basic) of $-0.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current EPS (Basic) is $-0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current EPS (Basic) of $-0.46. The current EPS (Basic) is $-0.46. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current EPS (Basic) is $-0.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price